Alnylam submits cta application for aln-khk, an investigational rnai therapeutic for the treatment of type 2 diabetes

Cambridge, mass.--( business wire )--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai (rna interference) therapeutics company, announced today that the company has submitted a clinical trial authorization (cta) application to health canada to initiate a phase 1/2 study of aln-khk, an investigational rnai therapeutic targeting ketohexokinase (khk) for the treatment of type 2 diabetes mellitus (t2dm). pending regulatory authority and ethic committee approvals, the company plans to begin enrollment in a phase 1/2 study in healthy overweight to obese volunteers and obese patients with t2dm in early 2023, and expects to report initial human data in late 2023.
ALNY Ratings Summary
ALNY Quant Ranking